| Characteristics . | All Participants . | EFV (n = 131) . | DTG (n = 92) . | DTG/MVC (n = 35) . | EFV vs DTG P Value . | EFV vs DTG/MVC P Value . |
|---|---|---|---|---|---|---|
| Age, y | 26 (23–31) | 26 (23–32) | 26 (23–32) | 24 (22–27) | .743 | .017 |
| Sex, male, n (%) | 255 (99) | 128 (98) | 92 (100) | 35 (100) | .270 | 1.000 |
| Higher education, n (%) | 157 (61) | 83 (63) | 57 (62) | 17 (49) | .888 | .124 |
| Fiebig stage, n (%) | … | … | … | … | ||
| I–II (Ref) | 92 (36) | 58 (44) | 20 (22) | 14 (40) | .001 | .704 |
| III–V | 166 (64) | 73 (56) | 72 (78) | 21 (60) | ||
| Plasma HIV-1 RNA (log10 copies/mL) | 6.12 (5.34–6.84) | 5.91 (5.23–6.89) | 6.18 (5.57–6.84) | 6.04 (5.09–6.75) | .243 | .777 |
| CD4+ T-cell count, cells/mm3 | 359 (264–495) | 405 (276–507) | 332 (239–426) | 380 (276–511) | .006 | .559 |
| CD8+ T-cell count, cells/mm3 | 519 (319–959) | 532 (332–1108) | 455 (305–811) | 540 (334–941) | .098 | .906 |
| CD4/CD8 ratio | 0.71 (0.39–1.12) | 0.77 (0.38–1.12) | 0.71 (0.43–1.12) | 0.60 (0.35–0.93) | .891 | .670 |
| CD4/CD8 ≥1 | 80 (31) | 45 (34) | 27 (29) | 8 (23) | .469 | .226 |
| NPZ-4 composite score | 0.09 (−0.55 to 0.49) | 0.07 (−0.55 to 0.53) | 0.11 (−0.48 to 0.46) | 0.09 (−0.89 to 0.50) | .846 | .815 |
| PHQ-9 total score | 9 (5–13) | 9 (6–14) | 8 (4–13) | 6 (4–11) | .018 | .008 |
| PHQ-9 ≥10, n (%) | 105 (43) | 59 (49) | 36 (39) | 10 (29) | .165 | .051 |
| Distress thermometer | 5 (2.1–6.9) | 5.5 (3–7.5) | 3.7 (1.8–6) | 2.5 (1–6.5) | <.001 | .005 |
| Acute retroviral syndrome, n (%) | 198 (77) | 97 (74) | 78 (85) | 23 (66) | .069 | .395 |
| Estimated duration from HIV transmission to antiretroviral therapy initiation | 20 (13–26) | 19 (13–25) | 22 (14–27) | 18 (13–23) | .173 | .717 |
| Characteristics . | All Participants . | EFV (n = 131) . | DTG (n = 92) . | DTG/MVC (n = 35) . | EFV vs DTG P Value . | EFV vs DTG/MVC P Value . |
|---|---|---|---|---|---|---|
| Age, y | 26 (23–31) | 26 (23–32) | 26 (23–32) | 24 (22–27) | .743 | .017 |
| Sex, male, n (%) | 255 (99) | 128 (98) | 92 (100) | 35 (100) | .270 | 1.000 |
| Higher education, n (%) | 157 (61) | 83 (63) | 57 (62) | 17 (49) | .888 | .124 |
| Fiebig stage, n (%) | … | … | … | … | ||
| I–II (Ref) | 92 (36) | 58 (44) | 20 (22) | 14 (40) | .001 | .704 |
| III–V | 166 (64) | 73 (56) | 72 (78) | 21 (60) | ||
| Plasma HIV-1 RNA (log10 copies/mL) | 6.12 (5.34–6.84) | 5.91 (5.23–6.89) | 6.18 (5.57–6.84) | 6.04 (5.09–6.75) | .243 | .777 |
| CD4+ T-cell count, cells/mm3 | 359 (264–495) | 405 (276–507) | 332 (239–426) | 380 (276–511) | .006 | .559 |
| CD8+ T-cell count, cells/mm3 | 519 (319–959) | 532 (332–1108) | 455 (305–811) | 540 (334–941) | .098 | .906 |
| CD4/CD8 ratio | 0.71 (0.39–1.12) | 0.77 (0.38–1.12) | 0.71 (0.43–1.12) | 0.60 (0.35–0.93) | .891 | .670 |
| CD4/CD8 ≥1 | 80 (31) | 45 (34) | 27 (29) | 8 (23) | .469 | .226 |
| NPZ-4 composite score | 0.09 (−0.55 to 0.49) | 0.07 (−0.55 to 0.53) | 0.11 (−0.48 to 0.46) | 0.09 (−0.89 to 0.50) | .846 | .815 |
| PHQ-9 total score | 9 (5–13) | 9 (6–14) | 8 (4–13) | 6 (4–11) | .018 | .008 |
| PHQ-9 ≥10, n (%) | 105 (43) | 59 (49) | 36 (39) | 10 (29) | .165 | .051 |
| Distress thermometer | 5 (2.1–6.9) | 5.5 (3–7.5) | 3.7 (1.8–6) | 2.5 (1–6.5) | <.001 | .005 |
| Acute retroviral syndrome, n (%) | 198 (77) | 97 (74) | 78 (85) | 23 (66) | .069 | .395 |
| Estimated duration from HIV transmission to antiretroviral therapy initiation | 20 (13–26) | 19 (13–25) | 22 (14–27) | 18 (13–23) | .173 | .717 |
N = 258. Median (interquartile range) is provided unless specified.
Abbreviations: DTG, dolutegravir; EFV, efavirenz; HIV, human immunodeficiency virus; MVC, maraviroc; PHQ-9, patient health questionnaire.
| Characteristics . | All Participants . | EFV (n = 131) . | DTG (n = 92) . | DTG/MVC (n = 35) . | EFV vs DTG P Value . | EFV vs DTG/MVC P Value . |
|---|---|---|---|---|---|---|
| Age, y | 26 (23–31) | 26 (23–32) | 26 (23–32) | 24 (22–27) | .743 | .017 |
| Sex, male, n (%) | 255 (99) | 128 (98) | 92 (100) | 35 (100) | .270 | 1.000 |
| Higher education, n (%) | 157 (61) | 83 (63) | 57 (62) | 17 (49) | .888 | .124 |
| Fiebig stage, n (%) | … | … | … | … | ||
| I–II (Ref) | 92 (36) | 58 (44) | 20 (22) | 14 (40) | .001 | .704 |
| III–V | 166 (64) | 73 (56) | 72 (78) | 21 (60) | ||
| Plasma HIV-1 RNA (log10 copies/mL) | 6.12 (5.34–6.84) | 5.91 (5.23–6.89) | 6.18 (5.57–6.84) | 6.04 (5.09–6.75) | .243 | .777 |
| CD4+ T-cell count, cells/mm3 | 359 (264–495) | 405 (276–507) | 332 (239–426) | 380 (276–511) | .006 | .559 |
| CD8+ T-cell count, cells/mm3 | 519 (319–959) | 532 (332–1108) | 455 (305–811) | 540 (334–941) | .098 | .906 |
| CD4/CD8 ratio | 0.71 (0.39–1.12) | 0.77 (0.38–1.12) | 0.71 (0.43–1.12) | 0.60 (0.35–0.93) | .891 | .670 |
| CD4/CD8 ≥1 | 80 (31) | 45 (34) | 27 (29) | 8 (23) | .469 | .226 |
| NPZ-4 composite score | 0.09 (−0.55 to 0.49) | 0.07 (−0.55 to 0.53) | 0.11 (−0.48 to 0.46) | 0.09 (−0.89 to 0.50) | .846 | .815 |
| PHQ-9 total score | 9 (5–13) | 9 (6–14) | 8 (4–13) | 6 (4–11) | .018 | .008 |
| PHQ-9 ≥10, n (%) | 105 (43) | 59 (49) | 36 (39) | 10 (29) | .165 | .051 |
| Distress thermometer | 5 (2.1–6.9) | 5.5 (3–7.5) | 3.7 (1.8–6) | 2.5 (1–6.5) | <.001 | .005 |
| Acute retroviral syndrome, n (%) | 198 (77) | 97 (74) | 78 (85) | 23 (66) | .069 | .395 |
| Estimated duration from HIV transmission to antiretroviral therapy initiation | 20 (13–26) | 19 (13–25) | 22 (14–27) | 18 (13–23) | .173 | .717 |
| Characteristics . | All Participants . | EFV (n = 131) . | DTG (n = 92) . | DTG/MVC (n = 35) . | EFV vs DTG P Value . | EFV vs DTG/MVC P Value . |
|---|---|---|---|---|---|---|
| Age, y | 26 (23–31) | 26 (23–32) | 26 (23–32) | 24 (22–27) | .743 | .017 |
| Sex, male, n (%) | 255 (99) | 128 (98) | 92 (100) | 35 (100) | .270 | 1.000 |
| Higher education, n (%) | 157 (61) | 83 (63) | 57 (62) | 17 (49) | .888 | .124 |
| Fiebig stage, n (%) | … | … | … | … | ||
| I–II (Ref) | 92 (36) | 58 (44) | 20 (22) | 14 (40) | .001 | .704 |
| III–V | 166 (64) | 73 (56) | 72 (78) | 21 (60) | ||
| Plasma HIV-1 RNA (log10 copies/mL) | 6.12 (5.34–6.84) | 5.91 (5.23–6.89) | 6.18 (5.57–6.84) | 6.04 (5.09–6.75) | .243 | .777 |
| CD4+ T-cell count, cells/mm3 | 359 (264–495) | 405 (276–507) | 332 (239–426) | 380 (276–511) | .006 | .559 |
| CD8+ T-cell count, cells/mm3 | 519 (319–959) | 532 (332–1108) | 455 (305–811) | 540 (334–941) | .098 | .906 |
| CD4/CD8 ratio | 0.71 (0.39–1.12) | 0.77 (0.38–1.12) | 0.71 (0.43–1.12) | 0.60 (0.35–0.93) | .891 | .670 |
| CD4/CD8 ≥1 | 80 (31) | 45 (34) | 27 (29) | 8 (23) | .469 | .226 |
| NPZ-4 composite score | 0.09 (−0.55 to 0.49) | 0.07 (−0.55 to 0.53) | 0.11 (−0.48 to 0.46) | 0.09 (−0.89 to 0.50) | .846 | .815 |
| PHQ-9 total score | 9 (5–13) | 9 (6–14) | 8 (4–13) | 6 (4–11) | .018 | .008 |
| PHQ-9 ≥10, n (%) | 105 (43) | 59 (49) | 36 (39) | 10 (29) | .165 | .051 |
| Distress thermometer | 5 (2.1–6.9) | 5.5 (3–7.5) | 3.7 (1.8–6) | 2.5 (1–6.5) | <.001 | .005 |
| Acute retroviral syndrome, n (%) | 198 (77) | 97 (74) | 78 (85) | 23 (66) | .069 | .395 |
| Estimated duration from HIV transmission to antiretroviral therapy initiation | 20 (13–26) | 19 (13–25) | 22 (14–27) | 18 (13–23) | .173 | .717 |
N = 258. Median (interquartile range) is provided unless specified.
Abbreviations: DTG, dolutegravir; EFV, efavirenz; HIV, human immunodeficiency virus; MVC, maraviroc; PHQ-9, patient health questionnaire.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
